Orodispersible Tablets Market, By Drug Class (Analgesics, Antiemetics, Antipsychotics, Anti-inflammatory Drugs, Sedatives/Hypnotics, Antihypertensives, Others), By Disease Indication (Central Nervous System Disorders, Gastrointestinal Disorders, Cardiovas

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	160 Pages	Coherent Market Insights	November, 2023	CMI18366403

Best Price Guarantee
Price	from $4,500
Length	160 Pages
Publisher	Coherent Market Insights
Published Date	November, 2023
SKU	CMI18366403

Orodispersible Tablets Market, By Drug Class (Analgesics, Antiemetics, Antipsychotics, Anti-inflammatory Drugs, Sedatives/Hypnotics, Antihypertensives, Others), By Disease Indication (Central Nervous System Disorders, Gastrointestinal Disorders, Cardiovascular Disorders, Respiratory Disorders, Allergy and Asthma, Others), By Age Group (Pediatric Patients, Adult Patients, Geriatric Patients), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Orodispersible tablets (ODTs) are solid unit dosage forms that disintegrate or dissolve rapidly in the mouth without chewing and without the need for water. The demand for this dosage form has been increasing, especially in pediatric and geriatric patient populations who find swallowing conventional tablets difficult or uncomfortable. ODTs are formulated from various excipients including binders and disintegrants. The most common binders are methacrylic acid copolymers that have high internal strength to support the formulation of high dose drugs. These also have the property of water resistance, and are less sensitive to moisture than standard tablet formulations. The most popular disintegrants are mannitol and aspartame. Orodispersible tablets (ODTs) are a specialized dosage form designed to disintegrate rapidly in the oral cavity, often within a matter of seconds, without the need for additional water or chewing. This unique pharmaceutical formulation is primarily intended to improve patient compliance and convenience, particularly for those who have difficulty swallowing traditional solid oral dosage forms like tablets or capsules. ODTs are commonly used to administer medications, including pain relievers, antihistamines, and treatments for various medical conditions, especially when quick onset of action is essential.

Market Dynamics:

Increasing geriatric population across the globe is anticipated to drive growth of the global orodispersible tablets market. Elderly people prefer self-administration of medications for easy accessibility and convenience. Rising focus on healthcare facilities for the elderly also boosts the market growth.

However, increased pricing pressure is projected to hinder growth of the global orodispersible tablets market in the near future.

Key features of the study:

This report provides in-depth analysis of the global orodispersible tablets market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global orodispersible tablets market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AstraZeneca PLC, GlaxoSmithKline PLC, Novartis International AG, Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Pfizer Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global orodispersible tablets market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global orodispersible tablets market

Detailed Segmentation:

By Drug Class:
Analgesics
Antiemetics
Antipsychotics
Anti-inflammatory Drugs
Sedatives/Hypnotics
Antihypertensives
Others
By Disease Indication:
Pain Management
Allergy and Respiratory Disorders
Neurological Disorders
Gastrointestinal Disorders
Cardiovascular Disorders
Others
By Age Group:
Pediatric Patients
Adult Patients
Geriatric Patients
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East &Africa
Company Profiles:
AstraZeneca PLC
GlaxoSmithKline PLC
Novartis International AG
Johnson & Johnson Services, Inc.
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Pfizer Inc.
Cipla Limited
Dr. Reddy's Laboratories Ltd.
Sun Pharmaceutical Industries Ltd.
Lupin Pharmaceuticals, Inc.
Torrent Pharmaceuticals Ltd.
F. Hoffmann-La Roche Ltd.
Eisai Co., Ltd.
Takeda Pharmaceutical Company Limited

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Orodispersible Tablets, By Drug Class; Market Orodispersible Tablets, By Disease Indication; Market Orodispersible Tablets, By Age Group; Market Orodispersible Tablets, By Distribution Channel; Market Orodispersible Tablets, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Drivers; Market Dynamics; Increasing Prevalence of Chronic Diseases; Technological Advancements in Drug Delivery; Enhanced Patient Compliance and Convenience; Growing Focus on Patient-Centered Care; Restraints; High Development and Manufacturing Costs; Limited Drug Compatibility and Formulation Options; Opportunities; Increasing Demand for Personalized Medicine; Rising Adoption of Digital Health Solutions; Development of Innovative Taste-Masking Techniques; Focus on Fast-Dissolving Formulations; Impact Analysis; Key Highlights; Regulatory Scenario; Product Launches/Approvals; PEST Analysis; PORTER’s Analysis; Merger and Acquisition Scenario
4. Global Orodispersible Tablets Market– Impact of Coronavirus (COVID-19) Pandemic: COVID-19 Epidemiology; Supply Side and Demand Side Analysis; Economic Impact
5. Global Orodispersible Tablets Market, By Drug Class, 2018-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2019 – 2030; Segment Trends; Analgesics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Antiemetics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Antipsychotics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Anti-inflammatory Drugs; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Sedatives/Hypnotics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Antihypertensives; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
6. Global Orodispersible Tablets Market, By Disease Indication, 2018-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2019– 2030; Segment Trends; Pain Management; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Allergy and Respiratory Disorders; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Neurological Disorders; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Gastrointestinal Disorders; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Cardiovascular Disorders; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
7. Global Orodispersible Tablets Market, By Age Group, 2018-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2023– 2030; Segment Trends; Pediatric Patients; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Adult Patients; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Geriatric Patients; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
8. Global Orodispersible Tablets Market, By Distribution Channel, 2018-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2019– 2030; Segment Trends; Hospital Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
9. Global Orodispersible Tablets Market, By Region, 2018-2030, (US$ Bn): Introduction; Market Share Analysis, By Region, 2023 and 2030 (%); Y-o-Y Growth Analysis, For Region, 2019–2030; Country Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn); U.S.; Canada; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn); Brazil; Mexico; Argentina; Rest of Latin America; Middle East & Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn); GCC; Israel; North Africa; Central Africa; Rest of Middle East & Africa
10. Competitive Landscape: AstraZeneca PLC; Company Highlights; Product Portfolio; Key Developments; Financial Performance; Strategies; GlaxoSmithKline PLC; Novartis International AG; Johnson & Johnson Services, Inc.; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; Pfizer Inc.; Cipla Limited; Reddy's Laboratories Ltd.; Sun Pharmaceutical Industries Ltd.; Lupin Pharmaceuticals, Inc.; Torrent Pharmaceuticals Ltd.; F.Hoffmann-La Roche Ltd.; Eisai Co., Ltd.; Takeda Pharmaceutical Company Limited; Analyst Views
11. Section: Research Methodology; About us; *Browse 24 market data tables and 28 figures on "Global Orodispersible Tablets Market” - Global forecast to 2030